Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix[4]arene scaffold.
A potential anti-HIV and HCV drug candidate is highly desirable as coinfection has become a worldwide public health challenge. A potent compound based on a tetrabutoxy-calix[4]arene scaffold that possesses dual inhibition for both HIV and HCV is described. Structural activity relationship studies demonstrate the effects of lower-rim alkylation in maintaining cone conformation and upper-rim interacting head groups on the calix[4]arene play key roles for its potent dual antiviral activities.
Tsou
Lun K
LK
Department of Chemistry, Yale University, New Haven, CT 06520, United States. ktsou@rockefeller.edu
Dutschman
Ginger E
GE
Gullen
Elizabeth A
EA
Telpoukhovskaia
Maria
M
Cheng
Yung-Chi
YC
Hamilton
Andrew D
AD
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D047250:Calixarenes / Q000737:chemistry / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006678:HIV / Q000187:drug effects*; D015658:HIV Infections / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy*; D020128:Inhibitory Concentration 50; D008958:Models, Molecular; D015394:Molecular Structure
D000998:Antiviral Agents; D047250:Calixarenes